NDLI: Novel Scaled Bioequivalence Limits with Leveling-off Properties

Content Provider	Springer Nature Link
Author	Kytariolos, John Karalis, Vangelis Macheras, Pas Symillides, Mira
Copyright Year	2006
Abstract	(1) To develop novel scaled bioequivalence (BE) limits with levelling-off properties based solely on variability considerations and (2) to evaluate their performance in comparison to the classic unscaled BE limits 0.80–1.25, the expanded BE limits 0.75–1.33 and the recently proposed Geometric Mean Ratio (GMR)-dependent scaled BE limits BELscW (Karalis et al., Eur. J. Pharm. Sci., 26:54–61, 2005).Two model functions were used to ensure the gradual change of the BE limits from a starting value towards a predefined plateau value. Plots of the new BE limits and extreme GMR values ensuring BE as a function of the coefficient of variation (CV) were constructed. Two-period crossover BE studies with 12, 24, or 36 subjects were simulated assuming CV values from 10 to 60%. Power curves were constructed by recording the percentage of accepted BE studies as the true GMR was raised from 1.00 to 1.50. The percentage of the true GMR within the simulated BE limits vs. true GMR was used to evaluate the estimation accuracy of the scaled methods.Depending on the parameters’ values of the model functions, the scaled BE limits exhibit different performance. Four new scaled BE limits, showing favourable performance for the evaluation of average BE are presented. At low variability levels two of the novel BE limits show similar performance to the 0.80–1.25 criterion, while the other two (as expected from their design) appear to be less permissive. At high CV values (30, 40%) all new BE limits exhibit much higher statistical power than the 0.80–1.25 criterion. They show almost identical behavior with the expanded 0.75–1.33 limits and appear to be less permissive than BELscW. Finally, the percentage of the true GMR within the simulated BE limits vs. true GMR shows a sharp decline. Due to the absence of the GMR factor in the model functions a more accurate estimation of the new scaled BE limits, compared to BELscW, is observed.The new scaled BE limits appear to be highly effective at all levels of variation investigated and present satisfactory estimation accuracy.
Starting Page	2657
Ending Page	2664
Page Count	8
File Format	PDF
ISSN	07248741
Journal	Pharmaceutical Research
Volume Number	23
Issue Number	11
e-ISSN	1573904X
Language	English
Publisher	Kluwer Academic Publishers-Plenum Publishers
Publisher Date	2006-10-18
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	bioequivalence geometric mean ratio highly variable drugs scaled bioequivalence limits Biomedical Engineering Medical Law Biochemistry Pharmacy Pharmacology/Toxicology
Content Type	Text
Resource Type	Article
Subject	Organic Chemistry Pharmacology Molecular Medicine Pharmacology (medical) Biotechnology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Limits for the Scaled Average Bioequivalence of Highly Variable Drugs and Drug Products

Bioequivalence Approaches for Highly Variable Drugs and Drug Products

Novel Scaled Average Bioequivalence Limits Based on GMR and Variability Considerations

Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug Products

Inflation of the Type I Error: Investigations on Regulatory Recommendations for Bioequivalence of Highly Variable Drugs

Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA

Novel Direct Curve Comparison Metrics for Bioequivalence

Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable Drugs ( The AAPS Journal , Volume 10 , Issue 3 )

Evaluation of Bioequivalence of Highly Variable Drugs Using Clinical Trial Simulations. II: Comparison of Single and Multiple-Dose Trials Using AUC and Cmax

Novel Scaled Bioequivalence Limits with Leveling-off Properties

Similar Documents

Limits for the Scaled Average Bioequivalence of Highly Variable Drugs and Drug Products

Bioequivalence Approaches for Highly Variable Drugs and Drug Products

Novel Scaled Average Bioequivalence Limits Based on GMR and Variability Considerations

Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug Products

Inflation of the Type I Error: Investigations on Regulatory Recommendations for Bioequivalence of Highly Variable Drugs

Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA

Novel Direct Curve Comparison Metrics for Bioequivalence

Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable Drugs ( The AAPS Journal , Volume 10 , Issue 3 )

Evaluation of Bioequivalence of Highly Variable Drugs Using Clinical Trial Simulations. II: Comparison of Single and Multiple-Dose Trials Using AUC and Cmax

Novel Scaled Bioequivalence Limits with Leveling-off Properties